A CB2 and PPARγ agonist reduced collagen synthesis, deposition, and myofibroblast differentiation and reduced skin fibrosis when mice were treated with bleomycin (to create an animal model for systemic scleroderma). This evidence concerns the gene PPARG and systemic sclerosis.